Discover 657 paid clinical trials in Charleston, South Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 657
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
for
Eosinophilic Asthma
Location: North Charleston SC, Rock Hill SC, Chapel Hill NC,
Sponsor: Kymera Therapeutics, Inc.
Sex: All
Age: 18 - 70+
Code: NCT07323654
Phase 2, Recruiting
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
for
Asthma
Location: North Charleston SC, Albany GA, Birmingham AL,
Sponsor: Enveda Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT07301255
Phase 2, Recruiting
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
for
Venous Malformations, Lymphatic Malformations,
Location: Charleston SC
Sponsor: Kaken Pharmaceutical
Sex: All
Age: 2+
Code: NCT07285005
Phase 3, Recruiting
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
for
Healthy Volunteer, Atopic Dermatitis
Location: North Charleston SC, Union City GA, Birmingham AL,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18 - 65
Code: NCT07527923
Phase 1, Recruiting
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
for
Chronic Pruritus of Unknown Origin
Location: North Charleston SC, Savannah GA, Cullman AL, Miami FL,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07700056
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy
for
Lumbosacral Radiculopathy
Location: Charleston SC, Monroe NC, Jacksonville FL,
Sponsor: Vertanical GmbH
Sex: All
Age: 18+
Code: NCT06956014
Phase 3, Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
for
High Risk Cardiovascular Disease, Hypertension,
Location: Charleston SC, Columbia SC, Hinesville GA, Brunswick GA,
Sponsor: Alnylam Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07181109
Phase 3, Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
for
Transthyretin Amyloidosis With Cardiomyopathy
Location: Charleston SC, Charlotte NC, Gainesville GA, Tucker GA,
Sponsor: Alnylam Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07052903
Phase 3, Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
for
Depressive Disorder, Major
Location: Charleston SC, Atlanta GA, Tampa FL, Brandon FL,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18 - 70+
Code: NCT06559306
Phase 3, Recruiting
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
for
Cutaneous Sarcoidosis
Location: Charleston SC, Chapel Hill NC, Durham NC, Greenville NC,
Sponsor: Priovant Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06978725
Phase 2, Phase 3, Recruiting
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
for
Malignant Digestive System Neoplasm,
Location: Charleston SC, Augusta GA, Pinehurst NC, Greenville SC,
Sponsor: Wake Forest University Health Sciences
Sex: All
Age: 18+
Code: NCT07215624
Recruiting
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
for
Chronic Rhinosinusitis Without Nasal Polyps
Location: North Charleston SC, Orangeburg SC, Norfolk VA,
Sponsor: Optinose US Inc.
Sex: All
Age: 12 - 17
Code: NCT06850805
Phase 3, Recruiting
New
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)